NCT06679829 2026-02-19
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
4 trialsNCT06470971 2026-01-20
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT05684692 2025-10-30
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
Massachusetts General Hospital
Phase 2 Recruiting
NCT07106671 2025-08-06
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting